Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia From 2014 to 2020-Reference-Cited by-同舟云学术

Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia From 2014 to 2020

Published:2023-04-07 Issue:4 Volume:6 Page:e237467
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Cliff Edward R. Scheffer¹²,Kesselheim Aaron S.¹²,Rome Benjamin N.¹²,Feldman William B.¹²

Affiliation:

1. Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts

2. Harvard Medical School, Boston, Massachusetts

Abstract

This cross-sectional study analyzes trends in Medicare Part D use and spending on oral-targeted drugs for chronic lymphocytic leukemia from 2014 to 2020.

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2803484/cliff_2023_ld_230047_1680183111.00937.pdf

Reference6 articles.

1. Recognizing unmet need in the era of targeted therapy for CLL/SLL: “what’s past is prologue” (Shakespeare).;Mato;Clin Cancer Res,2022

2. Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia.;Eyre;Haematologica,2021

3. Competition and price among brand-name drugs in the same class: a systematic review of the evidence.;Sarpatwari;PLoS Med,2019

4. Generic price competition for specialty drugs: too little, too late?;Cole;Health Aff (Millwood),2018

5. Mikulic? M. Leading cancer drugs worldwide by revenue in 2020. Accessed October 24, 2022. https://www.statista.com/statistics/288538/top-cancer-drugs-based-on-revenue/

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era;Cancers;2023-07-29